Get the Stockscreener App
1.2801
0.01%
0.000100
After Hours:
1.28
-0.000100
-0.01%
Plus Therapeutics Inc Stock (PSTV) Forecast
The Plus Therapeutics Inc (PSTV) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $138.51, representing a +10,720% increase from the current price of $1.2801. The highest analyst price target is $137.91, and the lowest is $139.11.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month PSTV Price Target
Average 127.10
(+9,829% Upside)
Is Plus Therapeutics Inc (PSTV) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 60.13 | Neutral |
| STOCH(9,6) | 67.91 | Neutral |
| STOCHRSI(14) | 100.00 | Sell |
| MACD(12,26) | 0.0169 | Buy |
| ADX(14) | 9.9475 | Neutral |
| William %R | -24.18 | Neutral |
| CCI(14) | 146.05 | Buy |
Buy: 2
Sell: 1
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.2342
Buy
|
1.2413
Buy
|
| MA20 |
1.2121
Buy
|
1.2233
Buy
|
| MA50 |
1.2137
Buy
|
1.232
Buy
|
| MA100 |
1.3008
Sell
|
1.3081
Sell
|
| MA200 |
1.5427
Sell
|
1.4378
Sell
|
Buy: 6
Sell: 4
Neutral: 0
Summary: Buy
According to our latest analysis, PSTV could be considered a Potential Buy, with 17 technical analysis indicators signaling 8 Buy signals, 5 signaling Sell signals and 4 Neutral signals. This might be a good time to open fresh positions on PSTV, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 60.13 indicates that PSTV is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 67.91 indicates that PSTV is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 100 indicates that PSTV is oversold. This suggests that PSTV price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 9.9475 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 146.05 indicates that PSTV is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.
Long-term PSTV price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Plus Therapeutics Inc financial reports and earnings history, Plus Therapeutics Inc (PSTV) stock could reach $197.71 by 2030, $136.86 by 2040 and $450.97 by 2050. See the projected annual prices until 2050 of the Plus Therapeutics Inc stock below:
- Plus Therapeutics Inc (PSTV) is expected to reach an average price of $39.70 in 2035, with a high prediction of $45.51 and a low estimate of $39.70. This indicates an $3,001% rise from the last recorded price of $1.2801.
- Plus Therapeutics Inc (PSTV) stock is projected to chart a bullish course in 2040, with an average price target of $130.80, representing an $10,118% surge from its current level. The forecast ranges from a conservative $130.85 to a sky-high $136.86.
- Our analysts predict Plus Therapeutics Inc (PSTV) to jump 20,494% by 2045, soaring from $263.69 to an average price of $263.62, potentially reaching $271.56. While $263.69 is the low estimate, the potential upside is significant.
- Plus Therapeutics Inc (PSTV) stock is expected to climb by 2050, reaching an average of $440.89, a $34,342% jump from its current level. However, a wide range of estimates exists, with high and low targets of $450.97 and $440.99, respectively, highlighting the market's uncertainty.
Plus Therapeutics Inc Stock (PSTV) Year by Year Forecast
Plus Therapeutics Inc Stock (PSTV) Price Forecast for 2025
Plus Therapeutics Inc Stock (PSTV) is expected to reach an average price of $127.10 in 2025, with a high prediction of $145.70 and a low estimate of $108.51. This indicates an +9,829% rise from the last recorded price of $1.2801.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| March, 2025 | $141.73 | $139.11 | $137.91 | +10,972% |
| April, 2025 | $138.05 | $141.96 | $145.70 | +10,684% |
| May, 2025 | $140.89 | $141.64 | $139.54 | +10,906% |
| June, 2025 | $133.98 | $136.98 | $136.98 | +10,366% |
| July, 2025 | $125.19 | $129.54 | $132.10 | +9,680% |
| August, 2025 | $119.79 | $122.34 | $122.41 | +9,258% |
| September, 2025 | $103.73 | $115.88 | $116.71 | +8,003% |
| October, 2025 | $109.19 | $111.67 | $112.42 | +8,430% |
| November, 2025 | $107.53 | $108.51 | $107.16 | +8,300% |
| December, 2025 | $140.34 | $140.39 | $142.56 | +10,863% |
Plus Therapeutics Inc Stock (PSTV) Price Forecast for 2026
The predicted value for Plus Therapeutics Inc (PSTV) in 2026 is set at an average of $122.54. Estimates vary from a peak of $139.58 to a trough of $105.50, indicating an +9,473% surge from the present price of $1.2801.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $137.70 | $137.84 | $139.58 | +10,657% |
| February, 2026 | $135.06 | $135.21 | $136.98 | +10,451% |
| March, 2026 | $132.12 | $132.28 | $134.19 | +10,221% |
| April, 2026 | $127.43 | $127.79 | $131.21 | +9,854% |
| May, 2026 | $125.68 | $125.69 | $126.76 | +9,718% |
| June, 2026 | $123.44 | $123.49 | $124.52 | +9,543% |
| July, 2026 | $120.06 | $120.26 | $122.67 | +9,279% |
| August, 2026 | $116.64 | $116.87 | $119.11 | +9,011% |
| September, 2026 | $113.77 | $113.83 | $115.93 | +8,788% |
| October, 2026 | $111.50 | $111.64 | $113.06 | +8,610% |
| November, 2026 | $108.77 | $108.89 | $110.43 | +8,397% |
| December, 2026 | $105.43 | $105.50 | $107.75 | +8,136% |
Plus Therapeutics Inc Stock (PSTV) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Plus Therapeutics Inc (PSTV) is $88.17, with a high forecast of $104.71 and a low forecast of $71.64. This indicates an +6,788% increase from the last price of $1.2801.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $102.97 | $103.04 | $104.71 | +7,944% |
| February, 2027 | $100.39 | $100.39 | $101.97 | +7,742% |
| March, 2027 | $97.40 | $97.41 | $99.68 | +7,509% |
| April, 2027 | $94.80 | $94.87 | $96.67 | +7,305% |
| May, 2027 | $92.18 | $92.22 | $94.11 | +7,101% |
| June, 2027 | $88.74 | $88.74 | $91.30 | +6,832% |
| July, 2027 | $86.02 | $86.05 | $88.00 | +6,620% |
| August, 2027 | $83.57 | $83.60 | $85.33 | +6,429% |
| September, 2027 | $80.35 | $80.43 | $82.88 | +6,177% |
| October, 2027 | $77.66 | $77.68 | $79.68 | +5,967% |
| November, 2027 | $74.98 | $75.00 | $76.92 | +5,757% |
| December, 2027 | $71.60 | $71.64 | $74.28 | +5,493% |
Plus Therapeutics Inc Stock (PSTV) Price Forecast for 2028
In 2028, Plus Therapeutics Inc (PSTV) is projected to reach an average price of $52.52, with a high projection of $70.25 and a low estimate of $34.79. This indicates an +4,003% rise from the last price of $1.2801.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $68.56 | $68.66 | $70.25 | +5,256% |
| February, 2028 | $66.26 | $66.27 | $67.89 | +5,076% |
| March, 2028 | $62.85 | $62.86 | $65.30 | +4,810% |
| April, 2028 | $60.18 | $60.21 | $62.17 | +4,601% |
| May, 2028 | $56.92 | $56.93 | $59.51 | +4,346% |
| June, 2028 | $54.09 | $54.10 | $56.20 | +4,126% |
| July, 2028 | $51.43 | $51.44 | $53.39 | +3,918% |
| August, 2028 | $48.13 | $48.15 | $50.74 | +3,660% |
| September, 2028 | $45.45 | $45.46 | $47.43 | +3,451% |
| October, 2028 | $39.02 | $39.67 | $44.76 | +2,948% |
| November, 2028 | $35.69 | $35.76 | $37.29 | +2,688% |
| December, 2028 | $34.90 | $34.79 | $34.91 | +2,626% |
Plus Therapeutics Inc Stock (PSTV) Price Forecast for 2029
The 2029 price forecast for Plus Therapeutics Inc Stock (PSTV) is $88.62 on average, with a high prediction of $176.56 and a low estimate of $0.6756. This represents an +6,823% increase from the previous price of $1.2801.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $31.07 | $31.09 | $34.00 | +2,327% |
| February, 2029 | $28.33 | $28.66 | $30.22 | +2,113% |
| March, 2029 | $26.72 | $26.75 | $27.26 | +1,988% |
| April, 2029 | $24.02 | $24.23 | $26.05 | +1,777% |
| May, 2029 | $20.62 | $20.65 | $23.13 | +1,511% |
| June, 2029 | $17.51 | $17.64 | $18.56 | +1,268% |
| July, 2029 | $14.85 | $14.99 | $16.33 | +1,060% |
| August, 2029 | $11.21 | $11.24 | $14.03 | +775.44% |
| September, 2029 | $8.628 | $8.658 | $10.49 | +574.01% |
| October, 2029 | $5.2524 | $5.4505 | $7.8009 | +310.31% |
| November, 2029 | $2.7839 | $2.7839 | $4.4753 | +117.47% |
| December, 2029 | $199.06 | $0.6756 | $176.56 | +15,450% |
Plus Therapeutics Inc Stock (PSTV) Price Forecast for 2030
Plus Therapeutics Inc Stock (PSTV) is expected to reach an average price of $270.45 in 2030, with a high forecast of $325.39 and a low forecast of $215.52. This signifies an +21,028% surge from the last price of $1.2801.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $214.79 | $217.50 | $197.71 | +16,679% |
| February, 2030 | $216.87 | $218.23 | $209.37 | +16,842% |
| March, 2030 | $233.95 | $215.52 | $220.31 | +18,176% |
| April, 2030 | $148.44 | $253.89 | $232.60 | +11,496% |
| May, 2030 | $320.47 | $228.98 | $318.97 | +24,934% |
| June, 2030 | $326.75 | $329.16 | $324.81 | +25,425% |
| July, 2030 | $327.93 | $325.68 | $325.39 | +25,517% |
| August, 2030 | $319.51 | $322.66 | $325.22 | +24,860% |
| September, 2030 | $305.99 | $311.69 | $312.45 | +23,804% |
| October, 2030 | $310.17 | $308.24 | $308.83 | +24,130% |
| November, 2030 | $318.86 | $309.42 | $308.22 | +24,809% |
| December, 2030 | $309.69 | $309.99 | $313.30 | +24,093% |
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):